Fluicell AB

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0010831321
SEK
10.30
0.55 (5.64%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Fluicell AB stock-summary
stock-summary
Fluicell AB
Pharmaceuticals & Biotechnology
Fluicell AB is a Sweden-based company within healthcare industry. It commercializes a product portfolio for processing and studying of individual cells, primarily in the field of drug development. The Company’s products comprise research tools BioPen and Dynaflow Resolve. Tools enable researchers to study, process and measure drug impact on individual cells. Also, the Company develops bioprinting technology Biopixlar Retina in both two-dimensional (2D) and three-dimensional (3D) options. Biopixlar Retina creates complex tissue-like structures with control over positioning of individual cells.
Company Coordinates stock-summary
Company Details
Flojelbergsgatan 8C, Molndal , GOTEBORG None : 431 37
stock-summary
Tel: 46 31 3607481
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Stefan Tilk
Independent Chairman of the Board
Dr. Gavin Jeffries
Chief Technology Officer, Director
Prof. Owe Orwar
Director
Prof. Daniel Chiu
Independent Director
Mr. Carl Fhager
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Jun 2025)
Net Profit:
-3 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

SEK 18 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.33

stock-summary
Return on Equity

-58.84%

stock-summary
Price to Book

1.34